Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems

Footnotes

• Conflict of interest: M. Jevnikar has nothing to disclose.

• Conflict of interest: D. Montani reports grants and personal fees from Actelion, personal fees from GSK and MSD, grants from Bayer, outside the submitted work.

• Conflict of interest: L. Savale reports grants and personal fees from Actelion, personal fees from GSK and MSD, grants from Bayer, outside the submitted work.

• Conflict of interest: A. Seferian has nothing to disclose.

• Conflict of interest: E-M. Jutant has nothing to disclose.

• Conflict of interest: A. Boucly has nothing to disclose.

• Conflict of interest: M. Preda has nothing to disclose.

• Conflict of interest: J. Weatherald reports grants, personal fees and non-financial support from Janssen Inc. and Actelion, personal fees and non-financial support from Bayer, personal fees from Novartis, outside the submitted work.

• Conflict of interest: S. Bulifon has nothing to disclose.

• Conflict of interest: F. Parent has nothing to disclose.

• Conflict of interest: P. Brenot has nothing to disclose.

• Conflict of interest: E. Fadel has nothing to disclose.

• Conflict of interest: O. Sitbon reports grants and personal fees from Actelion, personal fees from GSK and MSD, grants from Bayer, outside the submitted work.

• Conflict of interest: G. Simonneau reports grants and personal fees from Actelion, personal fees from GSK and MSD, grants from Bayer, outside the submitted work.

• Conflict of interest: M. Humbert reports grants and personal fees from Actelion, personal fees from GSK and Merck, outside the submitted work.

• Conflict of interest: X. Jaïs reports grants and personal fees from Actelion, personal fees from GSK and MSD, grants from Bayer, outside the submitted work.